TickerHumNASDAQ · Healthcare · Drug Manufacturers—General
Amgen Inc. (AMGN)
As of Nov 11, 4:00 PM ET, Amgen (AMGN) last traded at $468.11, up 0.62% on the day. Its TickerHum research score is 68/100 (above average). It reported revenue of $38.9B for the twelve months ending 2026-09-30, up 8.2% year over year, with a 32.4% operating margin.
Ratings
- Valuation: 65/100 — Strongest input: price / sales (ttm) 6.5x. Weakest: free-cash-flow yield 3.8 %.
- Growth: 67/100 — Strongest input: diluted eps growth (ttm, yoy) +33.4 %. Weakest: revenue growth (ttm, yoy) +8.2 %.
- Profitability: 93/100 — Strongest input: return on equity 65.4 %. Weakest: net margin 24.1 %.
- Financial health: 17/100 — Strongest input: current ratio 1.48. Weakest: long-term debt / equity 3.60.
- Momentum: 87/100 — Strongest input: price vs 200-day average +23.3 %. Weakest: 3-month return +12.0 %.
- Attention: 52/100 — Strongest input: headlines in the last 7 days 40. Weakest: volume vs 3-month average 0.6x.
- Risk resilience: 79/100 — Based on annualised volatility (1y) 28.8 %, max drawdown (1y) -16.6 %.
- Data confidence: 98/100 — Strongest input: quote age (hours) 0 h. Weakest: inputs available 95 %.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $38.9B | TTM ending 2026-09-30 · 10-Q |
| Revenue growth | 8.2% | TTM ending 2026-09-30 · 10-Q |
| Net income | $9.39B | TTM ending 2026-09-30 · 10-Q |
| Diluted EPS | $17.25 | TTM ending 2026-09-30 · 10-Q |
| Operating margin | 32.4% | TTM ending 2026-09-30 · 10-Q |
| Net margin | 24.1% | TTM ending 2026-09-30 · 10-Q |
| Free cash flow | $9.58B | TTM ending 2026-09-30 · 10-Q |
| Cash | $13.19B | as of 2026-09-30 · 10-Q |
| Long-term debt | $51.61B | as of 2026-09-30 · 10-Q |
| Debt / equity | 3.60 | as of 2026-09-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000318154).
Comparable companies for Amgen
Selected by industry, business overlap and scale; these are not necessarily direct competitors.
- Amgen vs Gilead Sciences (AMGN vs GILD) — Same industry (Drug Manufacturers—General); market cap 0.83x; shares: oncology
- Amgen vs Merck & Co. (AMGN vs MRK) — Same industry (Drug Manufacturers—General); market cap 1.4x; shares: oncology
- Amgen vs Pfizer (AMGN vs PFE) — Same industry (Drug Manufacturers—General); market cap 0.66x; shares: oncology
- Amgen vs Bristol-Myers Squibb (AMGN vs BMY) — Same industry (Drug Manufacturers—General); market cap 0.51x; shares: oncology
- Amgen vs AbbVie (AMGN vs ABBV) — Same industry (Drug Manufacturers—General); market cap 2.1x; shares: oncology
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.